Navigation Links
CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
Date:2/21/2008

PALO ALTO, Calif., Feb. 21 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that 11 abstracts on clinical and preclinical studies have been accepted for presentation at the American College of Cardiology (ACC) 57th Annual Scientific Session, which will be held in Chicago, IL on March 29 - April 1, 2008.

Ranexa(R) (ranolazine extended-release tablets):

Ranolazine Suppresses Ectopic Activity in Isolated Rat Left Atrial Appendage; Poster; Sunday, March 30, 2008, 10:00 a.m. CST

Ranolazine Attenuates Palmitoyl-L-Carnitine Induced Ventricular Diastolic Dysfunction; Poster; Sunday, March 30, 2008, 11:00 a.m. CST

Ranolazine's Mechanism of Action for Reducing Myocardial Infarct Size is Independent of Changes in Coronary Collateral Blood Flow; Poster, Sunday, March 30, 2008, 11:00 a.m. CST

Ranolazine Prevents Ischemia-Induced ST Segment Changes and Left Ventricular Mechanical Dysfunction in Rabbits; Poster, Sunday, March 30, 2008, 11:00 a.m. CST

Ranolazine Increases Glucose Stimulated Insulin Secretion in Rats; Poster, Monday, March 31, 2008, 10:00 a.m. CST

Ranolazine Shortens Repolarization and Improves Myocardial Relaxation in Patients with Type-3 Long QT Syndrome; Poster, Monday, March 31, 2008, 10:00 a.m. CST

Chronic Kidney Disease, Cardiovascular Outcomes, and Treatment Disparities Following Non-ST Elevation Myocardial Infarction; Poster, Monday, March 31, 2008, 3:00 p.m. CST

Effects of Ranolazine on Disease-Specific Health Status and Quality of Life: Results from the MERLIN-TIMI 36 Randomized Trial; Poster, Monday, March 31, 2008, 3:00 p.m. CST

Myeloperoxidase Levels Associated with Risk of Cardiovascular Death and Heart Failure after Non-ST Elevation Acute Coronary Syndrome; Poster, Monday, March 31, 2008, 3:00 p.m. CST

Efficacy and Safety of Ranolazine in Chronic Angina: Observations from the Randomized, Double-blind, Placebo-controlled MERLIN-TIMI 36 Trial; Poster, Tuesday, April 1, 2008, 11:00 a.m. CST

Regadenoson

Heart Rate Response to Adenosine and Regadenoson in Diabetes Mellitus: A Marker of Autonomic Cardiac Neuropathy; Poster, Tuesday, April 1, 2008, 11:30 a.m. CST

Additional information regarding the ACC 57th Annual Scientific Sessions can be accessed at http://acc08.acc.org/Pages/default.aspx.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT- 6883, which is being developed for potential treatment of cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward- looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... NEWPORT BEACH, Calif. , June 23, 2016 /PRNewswire/ ... offering new biological discoveries to the medical community, has ... and co-founder Matthew Nunez . "We ... provide us with the capital we need to meet ... funding will essentially provide us the runway to complete ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... -- Research and Markets has announced the addition of ... offering. The global biomarkers ... in 2013. The market is expected to grow at a five-year ... increasing from $50.6 billion in 2015 to $96.6 billion in 2020. ... period (2015 to 2020) are discussed. As well, new products approved ...
Breaking Biology Technology:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):